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Abstract 
The broad substrate capacity of the intestinal oligopeptide transporter, PepT1, has made it a key target 
of research into drug delivery. Whilst the substrate capacity of this transporter is broad, studies have 
largely been limited to small peptides and peptide-like drugs. Here, we demonstrate for the first time 
that a diverse range of drugs can be targeted towards transport by PepT1 using a hydrolysis resistant 
carrier. Eleven prodrugs were synthesised by conjugating modified dipeptides containing a thioamide 
bond to the approved drugs ibuprofen, gabapentin, propofol, aspirin, acyclovir, nabumetone, atenolol, 
zanamivir, baclofen and mycophenolate. Except for the aspirin and acyclovir prodrugs, which were 
unstable in the assay conditions and were not further studied, the prodrugs were tested for affinity and 
transport by PepT1 expressed in Xenopus laevis oocytes: binding affinities ranged from approximately 
0.1 to 2 mM. Compounds which showing robust transport in an oocyte trans stimulation assay were 
then tested for transcellular transport in Caco-2 cell monolayers: all five tested prodrugs showed 
significant PepT1-mediated transcellular uptake. Finally, the ibuprofen and propofol prodrugs were 
tested for absorption in rats:  following oral dosing the intact prodrugs and free ibuprofen were 
measured in the plasma. This provides proof-of-concept for the idea of targeting poorly bioavailable 
drugs towards PepT1 transport as a general means of improving oral permeability.  
Keywords 
Prodrug; membrane transporter; intestine; PepT1; drug delivery 
 
 
 TOC Graphic  
 
 
Introduction 
The oral bioavailability of a compound is a crucial factor in its success or failure as a therapeutic agent, 
particularly given the convenience of this route of administration. There are two main mechanisms of 
absorption from the GI tract: passive diffusion [1] and carrier mediated transport [2].  The oral 
bioavailability of poorly absorbed drugs can be improved either by modifying their physicochemical 
properties to aid passive diffusion and/or by targeting of the compounds towards carrier mediated 
transport [3-5].  
PepT1 is a proton coupled oligopeptide transporter expressed principally in the small intestine and the 
proximal tubule of the kidney [6]. It has a broad substrate specificity including most di- and tripeptides, 
β-lactam antibiotics and ACE inhibitors [7]. 
There are many examples of targeting PepT1 to improve the oral bioavailability of pharmacologically 
active compounds, usually by modifying them so that they resemble the natural di- or tripeptide 
substrates [8-13].  We have patented [14] a set of thiodipeptide substrates (such as A and B) that we 
hope can act as “carriers” for drug transport by PepT1 generally, and have previously published our 
work on model systems demonstrating that a variety of linkers can be employed [15, 16]. The basic 
premise is illustrated in Figure 1 in which drugs are conjugated directly or by a linker to our 
thiodipeptides, converting them into prodrugs that are PepT1 substrates. 
 Figure 1. PepT1 as a drug delivery target. Drugs are attached to the side-chains of the seryl (A) or aspartyl (B) thiodipeptide 
carriers, directly or via linkers, forming prodrug substrates of PepT1.  
In this paper, we apply the results of our previously reported characterisation of the structure-transport 
relationships for PepT1 [15] to drug delivery challenges and report proof-of-concept studies that 
validate our thiodipeptide carriers as a general approach for targeting a variety of drugs towards PepT1 
mediated transport. We focused on two major areas that we felt could benefit from our thiodipeptide 
drug delivery technology:  
i) Drugs with GI side effects. A common class of such drugs are the NSAIDs, as exemplified by aspirin and 
ibuprofen [17]. Whilst these drugs have high oral bioavailability, they also can cause severe gastric side 
effects. If a prodrug strategy could be developed so that bioavailability was retained, but active drug was 
not released close to the GI tract, such side effects might be significantly reduced. Prodrugs 1, 4 and 6-7 
of ibuprofen, aspirin and nabumetone respectively (Figure 2) were synthesized to explore this area. 
ii) Drugs with poor oral bioavailability. This is a major challenge in drug development. A search of 
ChEMBL [18] identified several marketed drugs with low, highly variable or no oral bioavailability [17]: 
gabapentin (an anticonvulsant and analgesic); baclofen (a GABA receptor agonist); propofol 
(chemotherapeutic nausea and intractable migraine); zanamivir (treatment and prophylaxis of influenza) 
and mycophenolic acid (an immunosuppressant). Prodrugs 2, 3, 5, and 8-11 (Figure 2) were synthesized 
to prove our concept in this important area. 
 
 Figure 2. Rationally designed prodrugs to target PepT1 (parent drug in brackets). 
  
Chemistry 
The synthesis of the protected serine and aspartate carrier thiodipeptides (12 and 13), nabumetone 
prodrugs 6-7 and ibuprofen prodrug 1 have been reported previously [15, 16]. Our chosen drugs could 
readily be attached to the appropriate carrier using standard coupling reagents, except for the aspirin 
prodrug 4 (Table 1). This was synthesized by first using concentrated Mitsunobu conditions [19] with 
sonication to esterify the salicylic acid with triethylene glycol to give 22, then coupling this glycol ester to 
the aspartate carrier using standard coupling conditions (Scheme 1) to give 23. This indirect route was 
chosen because we were unable to accomplish direct esterification of aspirin with the serine carrier 
using a variety of coupling conditions. Deprotection was usually achieved in >85% yield using either a 
33% solution of TFA in DCM or neat formic acid, except for 5, for which decomposition was avoided by 
using phenol as solvent [20]. Since the NMR [15] of carriers 12 and 13 show no signs of epimerisation, 
and the coupling reactions employ only moderate bases with the reaction centre removed from chiral 
centres, we believe the rotamers observed in some protected intermediates and final compounds are 
not due to epimerisation. 
 
 
 
 
  
  
Drug Coupling Agent Compound (Yield) 
Gabapentin (Boc protected) HBTU 14 (22%) 
Propofol DCC 15 (38%) 
Acyclovir DCC 16 (96%) 
Atenolol (Boc protected) CDI 17 (36%) 
Zanamivir HATU 18 (11%) 
Baclofen (Boc protected) DCC 19 (65%) 
Mycophenolic acid HATU 20 (20%) 
Table 1. Synthesis of protected pro-drugs (non-optimized yields) 
 
 
Scheme 1. Synthesis of protected aspirin pro-drug. (i) PPh3, triethylene glycol, DIAD, THF, rt, sonication, 15 min. (ii) 13 [15], 
HBTU, DIPEA, DMF, rt, 4 days. 
 
Results and Discussion 
The results of binding studies, trans-stimulation and Caco-2 monolayer assays are summarised in Table 
2. The binding affinities of all prodrugs for PepT1 were determined by measuring the concentration at 
which they inhibit uptake of radiolabelled D-Phe-L-Gln in Xenopus laevis oocytes expressing rabbit 
PepT1. Inhibition constants were calculated from standard Michaelis-Menten kinetics [21, 22]. PepT1 is 
a low affinity, high capacity transporter and compounds with an affinity < 1 mM are generally classed as 
high affinity binders of the transporter. Figure 3 shows the data for prodrugs 1 and 3, which are 
representative of those determined for all the prodrugs. Prodrugs 4 and 5 had limited stability in the pH 
5.5 assay buffer (multiple HPLC peaks), and so no reliable affinity or transport data could be generated. 
Compound  
(parent drug) 
Ki (mM) Trans-stimulated 
efflux? 
Overall Papp 
(x 10-6 cm s-1) 
(Normaliseda) 
PepT1 Papp 
(x 10-6 cm s-1) 
Normaliseda 
FSA (control) 0.32 ± 0.08 No 3.0 ± 0.5 (1.00) 1.9 ± 0.5 (1.00) 
1 (ibuprofen) 0.26 ± 0.03 Yes 3.7 ± 0.2 (1.29) 2.1 ± 0.3 (1.07) 
2 (gabapentin) 1.01 ± 0.33 Yes 0.6 ± 0.1 (0.46) 0.4 ± 0.1 (0.69) 
3 (propofol) 0.92 ± 0.19 Yes 0.5 ± 0.1 (0.41) 0.5 ± 0.1 (0.89) 
4 (aspirin) ndb    
5 (acyclovir) ndb    
6c (nabumetone) 0.08 ± 0.02 Yes 9.7 ± 0.1 (1.94) 4.4 ± 0.2 (1.30) 
7c (nabumetone) 0.46 ± 0.09 Yes 7.8 ± 0.2 (3.78) 6.3 ± 0.1 (6.52) 
8 (atenolol) 0.44 ± 0.15 No nd nd 
9 (zanamivir) 0.13 ± 0.02 No nd nd 
10 (baclofen) 1.87 ± 0.26 No nd nd 
11 (mycophenolate) 0.21 ± 0.08 Weak nd nd 
Table 2. Summary of in vitro affinity and transport studies on rationally design prodrugs in oocytes and Caco-2 monolayers. a 
The PheΨ[CS-NH]-Ala (FSA) value is the mean ± RSD of six separate experiments with at least three monolayers. All 
other results are the mean ± RSD of one experiment with at least three monolayers. The normalized figure is to the 
FSA value recorded in that experiment. b Prodrug was unstable to assay buffer (pH 5.5). c Previously reported data [16]. 
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Figure 3. The Ki of prodrugs 1 and 3 for rabbit PepT1 expressed in Xenopus laevis oocytes. 
 
As binding studies only show affinity for PepT1 and do not provide information as to whether the 
compound is a substrate or an inhibitor, further transport experiments were undertaken. Trans-
stimulation assays were performed using radiolabelled [3H]-D-Phe-L-Gln efflux from rabbit PepT1 
expressing oocytes in the presence of 10 mM pro-drug. As controls, 10 mM Gly-L-Gln (a standard PepT1 
substrate) or buffer lacking a substrate (negative control) were used. Figure 4 shows the efflux data for 
the compounds summarised in Table 2. 
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Figure 4. Effect of incubation of 10 mM prodrugs on the trans-stimulation efflux of radiolabelled [3H]-D-Phe-L-Gln, compared to 
the known PepT1 substrate GlyGln 
Prodrugs 1-3, 6-7 and 11 induced statistically significant trans-stimulation efflux in oocytes, thereby 
demonstrating PepT1 mediated transport [21, 22]. Most of these induced similar or greater efflux than 
GlyGln, however prodrug 11 only weakly triggered efflux in comparison to GlyGln. 
Prodrugs that generated robust trans-stimulated efflux in oocytes were further in a Caco-2 monolayer 
assay to investigate further the extent and rate of trans-epithelial transport. Caco-2 cells were chosen as 
they are widely accepted as a good overall model for the small intestinal epithelium [23], although it has 
been suggested that Caco-2 cells may underestimate the in vivo trans-epithelial rate of transport [24]. 
Apical to basolateral transport of 2 mM pro-drug, applied to the apical side, was monitored by high 
performance liquid chromatography (HPLC) after one hour. The presence or absence of excess Gly-Gln 
allowed us to determine both the overall and PepT1 specific permeability (Table 2). The remaining pro-
drugs were significantly transported in both oocyte and Caco-2 monolayer assays. The PepT1 mediated 
Papp values are of similar magnitude to known PepT1 (pro)drug substrates [10, 16]. 
Based on these encouraging in vitro results, we elected to study 1 and 3 in vivo (Table 3), as simple 
examples of the two areas of interest to us. Administration of both 1 and 3 to rats resulted in intact 
prodrug being observed in the blood, with CMax of 0.2 and 16.7 µg/mL respectively observed. Release of 
ibuprofen was also observed upon administration of 1, with a relative bioavailability of 2% [25]. The shift 
in the TMax observed for ibuprofen following administration of 1 when compared to free ibuprofen (from 
1 hour for free ibuprofen to 3.5 hours for 1) is indicative of a change in absorption mechanism. The low 
bioavailability of ibuprofen can be explained by the relative stability of the prodrug 1 to metabolism, as 
estimated by its in vitro half-life upon incubation with rat liver homogenate of over 17 hours. 
 
 
Table 3. Preliminary in vivo results. Values are mean ± standard deviation for n = 3 male Sprague-Dawley rats. IV = intra venous 
dosing.   a As free base.  b As compared to L-Trp-L-Ala, which had a t1/2 of 0.15 hours under the same experimental conditions. 
Regrettably, we were unable to detect free propofol released following administration of prodrug 3 
because HPLC conditions to quantify free propofol could not be found. However, the relatively high CMax 
for the intact prodrug 3 is encouraging and despite the relative metabolic stability of 3 (7-hour half-life 
in rat liver homogenate) it is likely some free propofol would be available systemically. This is notable 
given the fact that propofol itself had no oral bioavailability in either rats or humans [26]. 
The low bioavailability of ibuprofen following administration of prodrug 1, combined with fact that both 
prodrug 1 and 3 were relatively resistant to liver metabolism indicates that further work is required to 
design effective prodrugs suitable for therapeutic application. Nevertheless, we believe 1 and 3 serve as 
promising preliminary proof-of-concept to the idea that targeting PepT1 using our thiodipeptides can be 
used as a general strategy to overcoming oral bioavailability issues in drug discovery and development. 
Conclusions 
PepT1 is described in the literature as having a broad substrate capacity but, in reality, it has been 
limited to date to small peptides and peptide-like drugs. To better harness the capacity of this 
transporter as a drug delivery target, a rational and general targeting approach is required. We report 
here our data supporting a thiodipeptide prodrug as such a general targeting approach in vitro and in 
vivo. 
We were excited to find that nine out of eleven of our rationally designed PepT1 targeting prodrugs 
displayed high affinity binding towards PepT1, and six of them triggered trans-stimulation. Additionally, 
prodrugs 1-3, as well as 6-7 (as previously reported) [16], were all significantly transported in Caco-2 
monolayers, with prodrugs 1 and 3 showing evidence of intact absorption in vivo. This provides proof-of-
concept that diverse drug types can be delivered via a PepT1 mediated pathway using thiodipeptide 
carriers, with implications for future drug design strategies. Preliminary in vivo data also supports the 
use of thiodipeptide prodrugs to confer oral bioavailability. 
The drugs exemplified represent examples of several classes of drugs for which oral delivery could be 
therapeutically interesting. These include thiodipeptide prodrugs of NSAIDs (e.g. 1, 4, 6-7), which have 
high oral activity but also suffer from significant GI side effects. Examples of drugs for which oral activity 
is absent (e.g. 3), low (e.g. 9), or highly variable (2, 10) have also been successfully modified using our 
thiodipeptide approach, to target the PepT1 transporter.  
Compound 
Dosea 
(mg kg-1) 
Assayed 
compound 
CMax 
(μg mL-1) 
AUC 
(μg h mL-1) 
tmax 
(h) 
Rat liver 
homgenateb 
t1/2 (h) 
Relative F 
(%) 
Ibuprofen 6 Ibuprofen 5.7 ± 0.6 14.0 ± 1.8 0.7 ± 0.3  100 [25] 
1 10 
Intact 1 0.2 ± 0.04 0.5 ± 0.1 1.0 ± 0.0 17.9 -  
Ibuprofen 0.2 ± 0.02 0.7 ± 0.1 3.2 ± 0.2  2.8 ± 0.3 
3 7.6 Intact 3 16.3 ± 1.8 3.2 ± 1.4 5.2 ± 0.8 7.3 - 
There is much future work to conduct before we can confidently say that rationally targeting PepT1 is a 
general strategy for oral drug delivery. In particular, the complete in vivo DMPK profile of our prodrugs 
needs to be established and future prodrugs need to be optimised for rapid liver and/or plasma esterase 
metabolism and release of free drug. Optimisation of the stability of the linker is also required, as 
evidenced by the instability of prodrugs 4 and 5. However, our previously reported work suggests that 
the transporter can accommodate a wide variety of linkers [15, 16], allowing scope to tailor a specific 
prodrug’s DMPK properties. 
The oral delivery of drugs is a major challenge in pre-clinical development and leads to significant 
shelving of promising lead candidates in drug discovery. Our prodrug approach may allow many such 
biologically active compounds to be re-evaluated by administration as PepT1 targeting thiodipeptide 
prodrugs. Our in vitro and preliminary in vivo data is highly encouraging and warrants further work. In 
particular, our recent report that large peptide drugs such as cyclosporine A [27] can be rationally 
targeted towards PepT1 using the same approach offers the tantalising possibility of PepT1 targeting as 
a solution to the delivery of both small and peptidic molecules.  
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Experimental Section 
In Vitro Biological Studies 
The Ki, trans-stimulation efflux and Caco-2 assays were performed as described previously [15, 16]. 
Fresh rat liver homogenate was prepared by isolating liver from euthanized male rats, according to 
approved Home Office procedures. The liver was chopped with scissors and rinsed with medium (0.25 M 
sucrose, 25 mM KCl, 5 mM MgCl2 and 50 mM Tris/HCl, pH7.5) to remove trapped blood. The liver was 
then homogenized in fresh medium with a loose-fitting dounce-type homogenizer and kept on ice. Liver 
homogenate was incubated with either 0. 5 mM compound 1 or 3, or L-Trp-L-Ala as a positive control, at 
37°C. 250 l aliquots of the homogenate were taken at 0, 0.25, 0.5, 1, 2, 6 and 24 hours. The samples 
were precipitated by addition an equal volume of 3% perchloric acid and centrifugation at 17000 g for 5 
minutes. The perchloric acid was neutralized with 250 l of 1 M KOH, and the sample subjected to a 
freeze / thaw cycle to precipitate the KClO4 salt before again being centrifuged. The supernatant was 
then analysed by HPLC as for the Caco-2 permeability studies [15, 16], and the half-life of the 
compounds calculated according to the method of Vig et al [28]. 
In vivo studies 
In vivo testing was carried out by Cyprotex Discovery Ltd., 15 Beech Lane, Macclesfield, Cheshire, SK10 
2DR, United Kingdom or Saretius Ltd, Science & Technology Centre, Earley Gate, University of Reading, 
Reading, Berkshire RG6 6BZ, United Kingdom. 
Each test compound was administered orally as solutions in distilled water (ibuprofen, 1) or 
polypropylene glycol (3) to three adult male Sprague-Dawley weighing 250-300 g, which were housed 
singly following jugular vein cannulation prior to administration of compound. Animals were given free 
access to food and water throughout the study and maintained under a 12-hour light/dark cycle with 
temperature and humidity controlled according to Home Office regulations. All compounds were well-
tolerated and no-adverse events were reported. 
Blood samples (230 µL) were taken from the carotid artery at the following time points and placed in 
heparinized tubes: predose, 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dose. After the final time point the 
animals were sacrificed by an overdose of anaesthetic. 
Blood samples were centrifuged to obtain the plasma, which was transferred to a separate labelled 
container. Aliquots from the individual time points for the three animals were analyzed singly. 80 µL of 
plasma was diluted with 20 µL of 1:1 ACN:water, then 800 µL chilled ACN was added, samples briefly 
vortex mixed and the centrifuged at 13000 rpm for 5 minutes at 4 °C. 500 µL of the resultant 
supernatant was further diluted with 500 µL water. 
20 µL sample was analyzed by LC-MS/MS using a C18 5 µm Gemini UHPLC column running a gradient of 
90% 0.04% acetic acid in water to 90% ACN over 3 minutes at a flow rate of 0.5 mL/min. MS data was 
acquired under multiple reaction monitoring conditions using a turbo spray ion source.  The 
concentration in the plasma was determined by comparison to standard curves of the administered 
compound prepared in blank plasma matrices and treated in an identical manner to the samples. 
Synthetic Chemistry 
Anhydrous solvents and reagents were obtained as follows: DMF was dried three times over molecular 
sieves (3 Å). THF was dried by distillation from sodium benzophenone ketyl, DCM and toluene by 
distillation from calcium hydride. All reactions were conducted at room temperature in dry glassware 
under a nitrogen atmosphere, unless otherwise stated. All chemicals were used directly from suppliers’ 
(Sigma-Aldrich) vessel without further purification, unless otherwise stated. Protected amino acids and 
HBTU were supplied by Novabiochem. 1H NMR spectra were recorded at 300, 400 or 500 MHz and 13C 
NMR spectra at 75, 100 or 125 MHz on a Bruker AC300, AC400, Avance II or Varian Unity INOVA 300 
spectrometers. Chemical shifts are denoted in ppm (δ) relative to the internal solvent standard. The 
splitting patterns for NMR spectra are designated as follows: s (singlet), br (broad), d (doublet), t 
(triplet), p (pentet), m (multiplet), or combinations thereof. Coupling constants (J) are designated in Hz 
and reported to 1 decimal place. Assignments were made with the aid of DEPT135, COSY and HMQC 
experiments. ES-MS (and HRMS) spectra were recorded on a Micromass LCT orthogonal acceleration 
time-of-flight mass spectrometer (positive ion mode) with flow injection via a Waters 2790 separation 
module autosampler. IR spectra were obtained using a Nicolet-Nexus 670/680 FT-IR or ATI Mattson 
Genesis Series FT-IR spectrometer and are quoted in cm-1. Optical rotations were measured at 589 nm in 
a 1 dm cell using an Optical Activity AA1000 polarimeter and are quoted in 10-2 deg cm2 g-1. Melting 
point determinations were made using a Stuart Scientific SMP1 apparatus and are uncorrected.  
Analytical TLC was performed on Merck silica gel 60 F254 aluminium backed plates. The plates were 
visualised under UV fluorescence (254 nm) or developed using ninhydrin (0.5% w/v butanol), 2-
bromocresol or acidified potassium permanganate solution with charring as necessary. Rf values are 
reported to the nearest 0.01. Mixed solvent system compositions are quoted as volumetric ratios. 
Column chromatography employed BDH silica gel (50-70 µm). Reverse phase analytical HPLC was 
performed on a Grace ODS (4.6 x 150 mm) column using a Gilson 306 pump with a flow rate of 1 mL min-
1. Detection was at 254 nm by a Gilson 115 UV detector. Reverse phase semi-preparative HPLC was 
performed on identical apparatus using a Varian ODS 10u (21.2 x 250 mm) column and a 15 mL min-1 
flow rate. DataApex Clarity™ software was used for integration and analysis. Retention times (in 
minutes) are quoted to one decimal place for the analytical system and are followed in parenthesis by 
the solvent conditions (v/v) used. Silica analytical and semi-preparative HPLC was performed using 
identical apparatus, software and respective flow rates with Silica PhenoSphere™ (4.6 x 250 mm) and 
Rainin Dynamax™ 60A (21.4 x 250 mm) columns respectively. Retention times (in minutes) are quoted to 
one decimal place for the analytical system and are followed in parenthesis by the solvent conditions 
(v/v) used. 
(S)-3-{2-[1-(tert-Butoxycarbonylamino-methyl)-cyclohexyl]-acetoxy}-2-((S)-2-tert-
butoxycarbonylamino-thiopropionylamino)-propionic acid tert-butyl ester (14) 
Gabapentin (85 mg; 0.5 mmol) and di-tert-butyl dicarbonate (130 mg; 0.6 mmol) were suspended in 1 
mL DMF. TEA (0.07 mL; 0.5 mmol) was added and the suspension stirred for four days at room 
temperature. A solution was formed after the first three hours of stirring. The DMF was removed in 
vacuo. HBTU (245 mg; 0.6 mmol) and DIPEA (0.11 mL; 0.6 mmol) were added to the residue, which was 
then redissolved in 1 mL DMF. The resultant solution was stirred at room temperature for 30 minutes. 
12 (132 mg; 0.4 mmol) in 1 mL DMF was then added and the solution stirred for three days at room 
temperature. The DMF was removed and the residue purified by flash column chromatography (4:1 
hexane:EtOAc → 1:1 hexane:EtOAc), followed by semi-preparative HPLC (2:1 hexane:EtOAc) to give title 
compound as a colourless oil (52 mg; 22%).  HPLC RT: 4.2 (2:1 hexane:EtOAc). [α]D31 (CHCl3; c = 3.68): 
−20.20. υmax (thin film): 3344, 2979, 2931, 2864, 1694, 1514, 1455, 1393, 1367, 1250, 1163, 1102, 1049, 
994, 913, 847, 733. δH (500 MHz, CDCl3): 1.51-1.26 (40H, m), 2.31-2.22 (2H, m), 3.07 (1H, dd, J = 14.0 & 
6.5), 3.17 (1H, dd, J = 14.0 & 6.5), 4.62-4.40 (3H, m), 4.91 (1H, s), 5.25 (1H, s), 5.50 (1H, s), 8.99 (1H, s). δC 
(125 MHz, CDCl3): 21.2, 21.8*, 25.7, 27.7, 27.8*, 28.2*, 28.2, 28.3*, 28.3, 33.6, 33.8, 37.4, 39.8, 46.9, 
56.1, 57.4, 62.7, 79.2, 79.7, 83.1, 154.9, 156.3, 156.9*, 166.9, 171.6, 206.3, 208.8*. HRMS: Calculated 
C29H52N3O8S: 624.3289, found: 624.3280.  * minor rotamer 
(S)-3-[2-(1-Aminomethyl-cyclohexyl)-acetoxy]-2-((S)-2-amino-thiopropionylamino)-propionic acid (2) 
Deprotection of 44 mg of 14 as for compound 1. Yield of 2 as di-TFA salt = 40 mg; 97%. HPLC RT: 4.6 
(10%, Chromolith®). δH (500 MHz, CD3OD): 1.36-1.45 (3H, m), 1.47-1.59 (10H, m), 2.57 (2H, q, J = 15.5), 
3.06 (2H, s), 4.35 (1H, q, J = 6.5), 4.53 (1H, dd, J = 11.5 & 5.5), 4.62 (1H, dd, J = 11.5 & 3.5), 5.30 (0.1H, t, J 
= 5.0)*, 5.47 (0.9H, t, J = 5.0). δC (100 MHz, CD3OD): 19.5*, 19.7, 20.9*, 21.1, 22.7*, 25.4*, 25.6, 25.7*, 
32.9*, 33.0, 33.1*, 35.2, 36.5, 47.2, 53.8, 54.5, 63.1*, 63.3, 171.6, 201.5. MS: C15H27N3O4S m/z (ES-) 361.4 
[M-H++NH3].  * minor rotamer 
 (S)-2-((S)-2-tert-Butoxycarbonylamino-thiopropionylamino)-succinic acid 1-tert-butyl ester 4-(2,6-
diisopropyl-phenyl) ester (15) 
13 (120 mg; 0.3 mmol) and DCC (83 mg; 0.4 mmol) were stirred in 1 mL DMF for one hour at 0 °C. A 
precipitate was formed during this time. DMAP (7 mg; 0.1 mmol) and 2,6-diisopropylphenol (0.07 mL; 
0.4 mmol) were added. The suspension turned yellow immediately, was warmed to room temperature 
and stirred for 24 hours. The mixture was filtered and the residue washed with DCM. The solvent was 
removed in vacuo and the residue purified by flash column chromatography (DCM → 9:1 DCM:Et2O) to 
give title compound as a yellow oil (66 mg; 38%). Rf (95:5 DCM:Et2O): 0.58. [α]D31 (CHCl3; c = 3.00): 
+60.20. υmax (thin film): 3323, 2980, 2934, 1728, 1514, 1396, 1370, 1335, 1248, 1158, 1053, 912, 846, 
734. δH (500 MHz, CDCl3): 1.18 (12H, d, J = 5.5), 1.50-1.41 (21H, m), 2.95-2.70 (2H, m), 3.44-3.35 (1H, m), 
3.66-3.55 (1H, m), 4.49 (1H, t, J = 6.5), 5.13 (1H, s), 5.28 (1H, s), 7.15 (2H, d, J = 7.5), 7.22 (1H, t, J = 7.5), 
8.56 (0.2 H, br s)*, 8.69 (0.8H, d, J = 7.0). δC (100 MHz, CDCl3): 22.1, 22.8, 24.4, 27.8, 28.2, 34.2, 53.7, 
53.9, 83.4, 124.0, 126.8, 140.0, 145.2, 155.1, 168.1, 170.3, 204.9. 
(S)-2-((S)-2-Amino-thiopropionylamino)-succinic acid 4-(2,6-diisopropyl-phenyl) ester (3) 
Deprotection of 66 mg of 15 as for compound 1. Yield of 3 as TFA salt = 23 mg; 39%. HPLC RT: 4.8 (50%, 
Chromolith®). δH (500 MHz, CD3OD): 1.17 (6H, s), 1.18 (6H, s),  1.49 (0.8H, dd, J = 7.5 & 6.5)*, 1.49 (2.2H, 
d, J = 6.5), 2.85-3.05 (2H, m), 3.22-3.55 (2H, m), 4.27 (0.8H, q, J = 7.0), 4.33 (0.2, q, J = 7.0)*, 5.53 (1H, br 
s), 7.15-7.23 (3H, m). δC (100 MHz, CD3OD): 20.9, 23.5, 24.2, 28.3, 28.7, 35.7, 55.2, 55.7, 125.1, 127.9, 
141.8, 146.8, 171.1, 171.9, 202.3. MS: C19H28N2O4S m/z (ES+) 381.1 [M+H+]. HRMS: Calculated 
C19H29N2O4S: 381.1843, found: 381.1836.  * minor rotamer 
2-(2-Oxo-propyl)-benzoic acid 2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethyl ester (21) 
A suspension of aspirin (345 mg; 1.9 mmol), triphenylphosphine (545 mg; 2.1 mmol) and triethylene 
glycol (0.27 mL; 2.0 mmol) in 0.7 mL THF was sonicated to give a viscous solution. DIAD (0.40 mL; 2.0 
mmol) was then added over 5 minutes to give a yellow solution. This was sonicated for 15 minutes at 
room temperature. The solution was purified by flash column chromatography (4:1 hexane:EtOAc → 
EtOAc) to give crude product. This was further purified by flash column chromatography (9:1 DCM:Et2O 
→ EtOAc) to give the title compound as a colourless oil (294 mg; 49%). Rf (EtOAc): 0.29. υmax (thin film): 
3489, 2875, 1768, 1723, 1608, 1486, 1453, 1369, 1295, 1258, 1197, 1123, 1082, 916, 754. δH (500 MHz, 
CDCl3): 2.35 (3H, s), 2.63 (1H, br s), 3.58 (2H, t, J = 4.4), 3.66 (4H, br s), 3.68-3.70 (2H, m), 3.78 (2H, t, J = 
4.7), 4.43 (2H, t, J = 4.7), 7.09 (1H, d, J = 8.2), 7.30 (1H, t, J = 7.6), 7.55 (1H, t, J = 8.2), 8.05 (1H, d, J = 7.9). 
δC (150 MHz, CDCl3): 20.9, 61.6, 64.0, 69.0, 70.2, 70.6, 72.4, 123.0, 123.7, 125.9, 131.8, 133.9, 150.6, 
164.4, 169.7. MS: C15H20O7 m/z (ES+) 335.1 [M+Na+]. HRMS: Calculated C15H20O7Na: 335.1101, found: 
335.1092. 
(S)-2-((S)-2-tert-Butoxycarbonylamino-thiopropionylamino)-succinic acid 4-(2-{2-[2-(2-acetoxy-
benzoyloxy)-ethoxy]-ethoxy}-ethyl) ester 1-tert-butyl ester (22) 
13 (142 mg; 0.4 mmol) and HBTU (294 mg; 0.8 mmol) was dissolved in 2 mL DMF. DIPEA (0.08 mL; 0.5 
mmol) was added to the colourless solution which turned orange almost immediately. The solution was 
stirred at room temperature for one hour at which time it was red/brown in colour. 21 (287 mg; 0.9 
mmol) in 1 mL DMF was then added and the solution stirred for four days at room temperature. The 
DMF was removed under vacuum and the residue purified by flash column chromatography (1:1 
hexane: EtOAc → EtOAc) to give the title compound as a yellow oil (202 mg; 80%). Rf  (1:1 
hexane:EtOAc): 0.26. [α]D20 (CHCl3; c = 1.14): +27.94. υmax (thin film): 3337, 2978, 2934, 1762, 1723, 1607, 
1513, 1453, 1393, 1254, 1195, 1083, 1047, 1012, 916, 848. δH (500 MHz, CDCl3): 1.39-1.42 (21H, m), 2.32 
(3H, s), 3.00 (1H, dd, J = 17.1 & 3.9), 3.11 (1H, dd, J = 17.1 & 4.0), 3.62-3.67 (6H, m), 3.75-3.77 (2H, m), 
4.12-4.23 (2H, m), 4.40 (2H, t, J = 4.7), 4.42-4.48 (1H, m), 5.17-5.18 (0.8H), 5.24-5.25 (0.2H, m)*, 5.31-
5.33 (0.2H)*, 5.44 (0.8H), 7.07 (1H, dd, J = 7.9 & 1.1), 7.27 (1H, ddd, J = 7.9, 7.6 & 1.1), 7.53 (1H, ddd, J = 
7.9, 7.6 & 1.6), 8.01 (1H, dd, J = 7.9 & 1.6), 8.66 (0.8H, d, J = 7.5), 8.73 (0.2H, d, J = 7.5)*. δC (150 MHz, 
CDCl3): 20.8, 21.8, 27.7, 28.1, 34.7, 53.9, 56.8, 63.8 & 69.0, 68.9, 70.2, 70.4,  79.9, 82.9, 122.9, 123.7, 
125.8, 131.7, 133.8, 150.5, 154.7, 164.2, 168.2, 169.5, 170.3, 170.8*, 205.0. MS: C31H46N2O12S m/z (ES+) 
688.6 [M+NH4+]. HRMS: Calculated C31H50N3O12S: 688.3110, found: 688.3125.  * minor rotamer 
(S)-2-((S)-2-Amino-thiopropionylamino)-succinic acid 4-(2-{2-[2-(2-acetoxy-benzoyloxy)-ethoxy]-
ethoxy}-ethyl) ester (4) 
Deprotection of 65 mg of 22 as for compound 1. Yield of 4 as TFA salt = 52 mg; 85%. Rf  (1:1:1:1 
EtOAc:BuOH:H2O:CH3CO2H): 0.42. [α]D24 (MeOH; c = 0.82): +29.44. δH (500 MHz, D2O): 1.40 (0.4H, d, J = 
6.9)*, 1.46 (2.6H, d, J = 6.9), 2.27 (3H, s), 2.87-3.01 (2H, m), 3.52-3.68 (6H, m), 3.72-3.78 (1.7H, m), 3.79-
3.82 (0.3H, m)*, 4.00-4.07 (0.3H, m)*, 4.08-4.15 (1.7H, m), 4.33 (1H, q, J = 6.9), 4.31-4.38 (1.7H, m),  
4.37-4.33 (0.3H, m)*, 5.15-5.28 (1H, m), 7.12 (1H, dd, J = 7.9 & 1.3), 7.34 (1H, ddd, J = 7.9, 7.6 & 1.3), 
7.60 (1H, ddd, J = 7.9, 7.6 & 1.6), 7.94 (1H, dd, J = 7.9 & 1.6). δC (150 MHz, D2O): 17.7*, 18.2, 18.6, 38.3, 
50.9, 51.1, 62.1, 65.9, 67.2, 67.9, 69.3, 120.1, 121.7*, 124.5, 129.4, 131.4, 137.4, 147.2, 160.5, 163.8, 
169.9, 170.9, 198.7. MS: C22H30N2O10S m/z (ES+) 515.4 [M+H+]. HRMS: Calculated C22H31N2O10S: 515.1694, 
found: 515.1697.  * minor rotamer. 
(S)-2-((S)-2-tert-Butoxycarbonylamino-thiopropionylamino)-succinic acid 4-[2-(2-amino-6-oxo-1,6-
dihydro-purin-9-ylmethoxy)-ethyl] ester 1-tert-butyl ester (16) 
13 (124 mg; 0.3 mmol) and DCC (68 mg; 0.3 mmol) were dissolved in 0.3 mL DMF and cooled to 0 °C. The 
reaction was stirred at this temperature for one hour during which time a white precipitate was formed. 
A solution of acyclovir (50 mg; 0.2 mmol) and DMAP (10 mg; 0.1 mmol) in 1.5 mL DMF was then added. 
The suspension was warmed to room temperature and stirred for 24 hours during which time the 
suspension changed from orange-brown to a brown-purple colour. The suspension was filtered and the 
filtrate washed with the minimum of DCM. The liquor was concentrated and the residue purified by 
flash column chromatography (95:5 CHCl3:MeOH → 9:1 CHCl3:MeOH) to give the title compound as a 
brown solid (123 mg; 96%). Rf (CHCl3:CH3OH, 9:1): 0.46. [α]D25 (CHCl3; c = 0.98): +7.20. max (thin film): 
3311, 3107, 2982, 2941, 1696, 1602, 1534, 1484, 1371, 1254, 1157, 1102, 1057, 845, 758. δH (CD3OD, 
300 MHz): 1.41 (3H, d, J = 6.8), 1.49-1.63  (18H, m), 2.88-3.03 (2H, m), 3.71-3.80 (2H, m), 4.14-4.22 (2H, 
m), 4.41-4.48 (1H, m), 5.23-5.28 (1H, m), 5.49 (2H, s), 7.88 (1H, s). δC (CD3OD, 75 MHz): 22.2, 28.5, 29.1, 
36.1, 56.2, 57.5, 65.2,65.2, 68.7, 68.7, 74.1, 79.9, 84.2, 118.7, 140.2, 153.2, 156.0, 156.9, 159.6, 170.3, 
172.0, 206.5. MS: C24H38N7O8S m/z (ES+) 584.1 [M+Na+]. HRMS: Calculated C24H38N7O8SNa: 584.2497, 
found: 584.2503.  
(S)-2-((S)-2-Amino-thiopropionylamino)-succinic acid 4-[2-(2-amino-6-oxo-1,6-dihydro-purin-9-
ylmethoxy)-ethyl] ester (5) 
A mixture of 16 (51 mg; 0.1 mmol) and phenol (179 mg; 1.9 mmol) was heated to 45 °C at which point 
the now liquid phenol had dissolved. Trifluoroacetic acid (0.03 mL; 0.4 mmol) was then added and the 
solution stirred at 45 °C for one hour. The solution was diluted with 2 mL EtOAc and washed three times 
with 3 mL water. The EtOAc was removed in vacuo and the residue sequentially taken up in DMF and 
water, both of which were removed under vacuum. The resultant residue, which was free from phenol 
contamination, was redissolved in 5 mL water and lyophilised to give di-TFA salt of 5 as an off white solid 
(28 mg; 44%). δH (D2O, 300 MHz): 1.37 (0.4H, d, J = 7.0)*, 1.50 (2.6H, d, J = 7.0), 2.80-2.91 (2H, m), 3.77-
3.84 (2H, m), 4.13-4.20 (2H, m), 4.26 (1H, q, J = 6.9), 5.03-5.11 (1H, m), 5.47 (2H, s), 8.09 (0.9H, s), 8.50 
(0.1H, s)*. δC (D2O, 75 MHz): 19.8, 34.7, 53.9, 54.2, 54.4, 54.8*, 64.2, 67.8, 74.3, 118.4, 138.5, 150.6, 
162.9, 171.8, 172.4, 201.2. MS: C15H21N7O6S m/z (ES+) 428.0 [M+H+]. HRMS: Calculated C15H22N7O6S: 
428.1347, found: 428.1336.  * minor rotamer. 
(S)-4-((S)-3-(4-(2-amino-2-oxoethyl)phenoxy)-1-(tert-butoxycarbonyl)propan-2-yl) 1-tert-butyl 2-((S)-2-
(tert-butoxycarbonyl)propanethioamido)succinate (17) 
S(-)-Atenolol (100 mg, 0.37 mmol) was dissolved in water (10 ml) containing (59 mg, 0.56 mmol) of 
sodium carbonate and the mixture was cooled to 0 0C with stirring. Then, the solution of di-tert. butyl 
dicarbonate (125 mg, 0.57 mmol) in 10 ml of 1,4-dioxane was slowly added at the same temperature. 
The mixture was stirred overnight at room temperature, evaporated in vacuo to get white solid, diluted 
with 20 ml of water, and extracted with three portions of ethyl acetate. The ethyl acetate solution was 
washed with brine, dried (MgSO4) and evaporated in vacuo to afford white solid (131 mg). A solution of 
this in 10 mL MeCN was slowly added over 20 minutes to a solution of 13 (150 mg, 0.39 mmol) in MeCN 
(15 ml) containing (117 mg, 0.71 mmol) of 1,1’-carbonyl diimidazole and (14 mg, 0.2 mmol) of imidazole. 
The mixture was stirred for 3 days at room temperature under the inert atmosphere. The precipitated 
solid was filtered off and the filtrate was evaporated in vacuo to get thick brown gel, which can further 
diluted with 30 ml of EtOAc, and washed with 2M HCl (2 x 10 ml), saturated aqueous NaHCO3 (3 x 10 
ml), water (2 x 10ml) and finally with the brine (20 ml), dried (MgSO4) and evaporated in vacuo to afford 
white crude solid. The residue was purified by flash column chromatography (3:7 petrol:EtOAc → EtOAc) 
to give desired product as a white solid (130 mg; 36%). M.p. 64-67 °C. Rf 0.40 [Petrol-EtOAc 2:8]. [α]D25 
(CHCl3; c = 0.028): 34.97. υmax (neat)/cm-1  3675, 3338, 2973, 2901, 1690, 1667, 1614, 1511, 1453, 1406, 
1393, 1366, 1242, 1155, 1050, 900, 846, 775, 731, 435. δH (300 MHz, CDCl3):  1.10 (6H, s), 1.32-1.42 
(30H,  m),  2.91 (1H, br s), 3.35 (1H, br s),  3.40-3.45 (3H, m), 3.92-4.12 (3H, m), 4.33-4.45 (1H, m), 5.10-
5.22 (1H,  m), 5.22-5.30 (1H, m), 5.30-5.42 (1H, m), 5.70-5.80 (1H, m), 6.82 (2H, d, J = 8.7), 7.15 (2H, d, J 
= 8.5). δC (75 MHz, CDCl3): 17.5, 21.0, 22.1, 22.6, 23.8, 27.8, 28.2, 28.4, 29.3, 29.6, 31.9, 34.9, 42.3, 43.2, 
53.9, 56.0, 57.0, 67.4, 80.1, 83.1, 115.1, 127.5, 130.6, 154.8, 157.6, 168.2, 174.1, 205.4. HRMS: 
Calculated C35H56N4O10S 725.3790, found 725.3795. MS C35H55N4O10S m/z (ES+) 725.37 [M+H+]. 
(S)-4-((S)-3-(4-(2-amino-2-oxoethyl)phenoxy)-1-(isopropylamino)propan-2-yloxy)-2-((S)-2-
aminopropanethioamido)-4-oxobutanoic acid (8) 
17 (100 mg, 0.138 mmol) was dissolved in 3 mL 97% formic acid. The solution was refluxed at 100 0C for 
three hours, followed by room temperature for overnight. The excess formic acid was then removed 
under high vacuum and the residue taken up in 2 mL distilled water. The fine suspension was filtered 
through a pipette plugged with glass wool and lyophilised to give the formate salt of 8 as a brown solid 
(53 mg; 76%). M.p. 118-121 °C. [α]D29 (MeOH; c = 0.028): -35.71. υmax (neat)/cm-1 3648, 3195, 2972, 2116, 
1869, 1830, 1738, 1667, 1583, 1510, 1456, 1380, 1346, 1298, 1240, 1176, 1082, 1066, 1046, 920, 879, 
798, 763, 668, 567, 518. δH (300 MHz, D2O):  1.1 (6H, d, J = 6.4), 1.42 (3H, d, J = 6.8),  2.73-2.92 (2H, m), 
3.22-3.41 (5H, m),  4.10-4.25 (3H, m), 4.91 (1H, t, J = 6.4), 5.31-5.42 (1H, m), 6.83 (2H, d, J = 8.7), 7.15 
(2H, d, J = 8.7), 8.23 (2H, s). δC (75 MHz, D2O): 17.7, 18.1, 19.2, 35.4, 40.6, 44.7, 51.4, 53.7, 56.7, 66.9, 
68.9, 114.9, 128.2, 130.5, 156.6, 167.8, 174.7, 177.7, 199.3. MS: C21H32N4O6S m/z (ES+) 468.2 [M+]. 
HRMS: Calculated for C21H32N4O6S 468.2043, found 468.1999 
(4S,5R,6R)-5-acetamido-6-((1R,2R)-3-((S)-4-tert-butoxy-3-((S)-2-(tert-
butoxycarbonyl)propanethioamido)-4-oxobutanoyloxy)-1,2-dihydroxypropyl)-4-guanidino-5,6-
dihydro-4H-pyran-2-carboxylic acid (18) 
A mixture of 13 (100 mg, 0.26 mmol), HATU (117mg, 0.30mmol) and DIPEA (0.15ml, 0.8mmol) in 
anhydrous DMF (10 ml) was stirred under nitrogen at 0 0C for 30 min. then a solution of Relenza (97 mg, 
0.29 mmol) in the mixture of dry DMF:DMSO(10 ml, 8:2) was added and stirring was continued  for 
another 3 days at room temperature. The reaction mixture were filtered off and the filtrate, plus a DMF 
washing, was evaporated in vacuo to get crude oil, which was further purified by chromatography, 
eluting with neat EtOAC to 1:1 (MeOH : EtOAC) to give desired product as an off white solid (20 mg, 
11%). M.p. 282-284 °C. Rf 0.40 [MeOH-EtOAc 3:7]. [α]D25 (CH3OH; c = 0.028): 35.71. υmax (neat)/cm-1  
3668, 3244, 2988, 2972, 2901, 1704, 1689, 1568, 1453,1405, 1322, 1250, 1155, 1049, 894, 609, 548. δH 
(300 MHz, CD3OD):  1.40 (22H, s),  2.00 (5H, s), 2.65 (1H, s), 3.00-3.10 (2H, m), 3.40 (1H, br s, -OH), 3.60-
3.75 (1H, m, 3.75-3.90 (1H, m), 4.00-4.25 (4H, m), 4.30-4.50 (3H, m), 5.20-5.25 (1H, m), 5.50 (1H, s). δC 
(75 MHz, D2O): 21.8, 26.9, 27.4, 47.6, 48.0, 51.0, 62.9, 67.9, 69.6, 75.2, 82.0, 103.8, 130.0, 149.0, 152.0, 
156.8, 170.0, 174.2, 184.0. MS: C28H46N6O12S m/z (ES+) 691.3 [M+H+]. HRMS Calculated for C28H47N6O12S 
691.2967, found 691.2973. 
(4S,5R,6R)-5-acetamido-6-((1R,2R)-3-((S)-3-((S)-2-aminopropanethioamido)-3-carboxypropanoyloxy)-
1,2-dihydroxypropyl)-4-guanidino-5,6-dihydro-4H-pyran-2-carboxylic acid (9) 
Deprotection of 100 mg of 18 as for compound 8. Yield of 9 as formate salt = 54 mg; 70%. M.p. 210-
212°C. [α]D29 (H2O; c = 0.057): 17.54. υmax (neat)/cm-1 3325, 3178, 2924, 2111, 1717, 1680, 1589, 1374, 
1324, 1282, 1146, 1041, 945, 768, 665. δH (300 MHz, D2O):  1.42 (3H, s), 1.92 (3H, s), 2.73-2.90 (3H, m), 
3.45-3.55 (2H, m), 3.73-3.82 (2H, m), 4.02-4.11 (1H, m), 4.15-4.30 (3H, m), 4.82-4.91 (1H, m), 5.53 (1H, 
s), 8.22 (1H, s). δC (75 MHz, D2O): 19.2, 21.8, 37.0, 47.5, 50.9, 53.0, 57.2, 62.0, 67.9, 69.6, 75.2, 104.1, 
136.0, 150.0, 156.8, 174.2, 180.0, 199.6. MS: C19H30N6O10S m/z (ES+) 534.2 [M+].  HRMS: Calculated for 
C19H30N6O10S 534.1744, found 534.1698. 
(R)-((S)-3-tert-butoxy-2-((S)-2-(tert-butoxycarbonyl)propanethioamido)-3-oxopropyl) 4-(tert-
butoxycarbonyl)-3-(4-chlorophenyl)butanoate (19) 
A mixture of Boc-baclofen (210 mg, 0.66 mmol), DCC (140.5 mg, 0.68 mmol) and DMAP (5 mg, 0.05 
mmol) in anhydrous DCM (20 ml) was stirred at room temperature for 15 min. under the inert 
atmosphere. Then, the solution of 12 (163 mg, 0.468 mmol) in 10 ml of DCM was slowly added at the 
same temperature. The mixture was stirred for 5 h at room temperature under the inert atmosphere. 
The precipitated solid was filtered off and the filtrate was evaporated in vacuo to get viscous liquid, 
which can further diluted with 30 ml of EtOAc, and washed with 2M HCl (2 x 10 ml), saturated aqueous 
NaHCO3 (3 x 10 ml), water (2 x 10 ml) and finally with the brine (20 ml), dried (MgSO4) and evaporated in 
vacuo to afford white crude solid. The residue was purified by flash column chromatography (9:1 
petrol:EtOAc → 7:3 petrol:EtOAc) to give desired product as a white solid (280 mg; 65%). M.p. 65-68 °C, 
Rf 0.50 [Petrol-EtOAc 8:2]. [α]D28 (CHCl3; c = 0.028): 71.43. υmax (neat)/cm-1: 3325, 2976, 2928, 2851, 1991, 
1693, 1626, 1574, 1510, 1493, 1449, 1411,  1393, 1366, 1310, 1244, 1190, 1108, 1088, 1048, 1014, 967, 
843, 827, 641, 534. δH (300 MHz, CDCl3): 1.42 (30H,  s),  2.53 (1H, dd, J = 7.5 & 6.4), 2.62 (1H, dd, J = 7.5 
& 6.4)  3.11-3.33 (2H, m), 3.33-3.42 (1H, m), 4.35 (1H, dd, J = 11.5 & 2.8), 4.41-4.53 (2H,  m), 4.55 (1H, 
dd, J = 11.5 & 2.4), 5.15-5.25 (1H, br m), 5.62 (1H, br s), 7.15 (2H, d, J = 8.5), 7.25 (2H, d, J = 8.3), 8.83 
(1H, br s). δC (75 MHz, CDCl3): 21.7, 27.8, 28.3, 28.38, 33.8, 37.6, 41.3, 57.1, 57.3, 62.9, 79.4, 82.7, 83.4, 
128.9, 132.9, 139.7, 155.9, 167.2, 170.9, 206.2. MS: C30H46ClN3O8S m/z (ES+) 644.3 [M+H+].  HRMS: 
Calculated for C30H47ClN3O8S 644.2195, found 644.2759. 
(S)-3-((R)-4-amino-3-(4-chlorophenyl)butanoyloxy)-2-((S)-2- aminopropanethioamido)propanoic acid 
(10) 
Deprotection of 100 mg of 19 as for compound 8. Yield of 10 as formate salt = 54 mg; 80%. M.p. 112-115 
°C. [α]D28 (H2O; c = 0.057): -17.54. υmax (neat)/cm-1: 3195, 2979, 2112, 1869, 1730, 1704, 1688, 1582, 
1511, 1490, 1456, 1379, 1241, 1164, 1110, 1089, 1050, 1013, 897, 823, 764, 668, 527; δH (300 MHz, 
D2O): 1.42 (3H,  s), 2.45-2.62 (1H, m), 2.62-2.75 (1H, m), 3.05-3.15 (1H, m), 3.15-3.35 (2H, m), 4.25-4.35 
(1H, m), 4.35-4.45 (1H,  m), 4.82-5.01 (2H, m), 7.22 (2H, d, J = 8.7), 7.31 (2H, d, J = 8.3), 8.35 (1H, s). δC 
(75 MHz, D2O): 19.2, 37.8, 39.1, 40.3, 53.7, 59.7, 63.9, 132.9, 133.3, 136.7, 137.6, 172.6, 173.0, 199.6. 
MS: C16H22ClN3O4S m/z (ES+) 388.1 [M+H+].  HRMS: Calculated for C16H23ClN3O4S 388.1098, found 
388.1102.  
(E)-((S)-3-tert-butoxy-2-((S)-2-(tert-butoxycarbonyl)propanethioamido)-3-oxopropyl) 6-(4-hydroxy-6-
methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate (20) 
A mixture of 12 (94 mg, 0.27 mmol), mycophenolic acid (100 mg, 0.31 mmol) and N-methylmorpholine 
(137 mg, 1.24 mmol) in anhydrous MeCN (10 ml) was stirred with 3 Å molecular sieves under nitrogen at 
20 °C for 2 h, then a solution of HATU (130 mg, 0.34 mmol) in MeCN (5 ml) was added and stirring was 
continued  for another 2 days. The reaction was monitored by TLC (7:3 Petrol : EtOAC). The reaction 
mixture were filtered off and the filtrate, plus an MeCN washing, was evaporated in vacuo to get crude 
solid, which can further diluted with 30 ml of EtOAc, and washed with 2M HCl (2x10ml), saturated 
aqueous NaHCO3 (3x10 ml), Water (2x10 ml) and finally with brine (20 ml), dried (MgSO4) and 
evaporated in vacuo to afford white crude solid, which was further purified by chromatography, eluting 
with 9:1 (Petrol : EtOAC) to 7.5:1 (Petrol : EtOAC) to give desired product as a white solid (40 mg, 20%). 
M.p. 69-72 °C. Rf 0.50 [Petrol-EtOAc 1:1]. [α]D20 (CHCl3; c = 0.028): 35.71. υmax (neat)/cm-1: 3326, 2976, 
2930, 2115, 1991, 1868, 1738, 1732, 1716, 1699, 1622, 1564, 1506, 1454, 1411, 1393, 1367, 1329, 1245, 
1179, 1130, 1049, 1038, 994, 969, 844, 792, 545. δH (300 MHz, CDCl3): 1.42 (21H,  s),  1.73 (3H, s), 2.14 
(3H, s), 2.22 (2H, t, J = 6.8), 2.25-2.35 (2H, m), 3.32 (2H, d, J = 6.8), 3.74 (3H, s), 4.35-4.53 (3H, m), 5.12-
5.23 (4H, m), 7.62 (1H, s), 8.53 (1H, m). δC (75 MHz, CDCl3): 11.6, 16.1, 21.7, 22.5, 27.8, 28.2, 32.6, 34.3, 
57.3, 61.0, 62.8, 70.1, 80.3, 83.5, 106.4, 116.7, 122.02, 122.8, 133.8, 144.1, 153.5, 163.6, 167.3, 172.8, 
172.9, 205.6. MS: C32H46N2O10S m/z (ES+) 651.3 [M+H+].  HRMS: Calculated for C32H47N2O10S 651.2951, 
found 651.2928. 
 (S)-2-((S)-2-aminopropanethioamido)-3-((E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-
dihydroisobenzofuran-5-yl)-4-methylhex-4-enoyloxy)propanoic acid (11) 
Deprotection of 100 mg of 20 as for compound 8. Yield of 11 as formate salt = 50 mg; 65%. M.p. 140-143 
0C. [α]D29 (H2O; c = 0.057): -35.09. υmax (neat)/cm-1: 3746, 3219, 2974, 2934, 2247, 2119, 1830, 1737, 
1731, 1688, 1668, 161, 1606, 1558, 1539, 1532, 1516, 1452, 1409, 1380, 1325, 1303, 1251, 1187, 1135, 
1107, 1075, 1033, 966, 938, 788, 642, 589, 542. δH (300 MHz, D2O): 1.22 (3H,  d, J = 3.8),  1.43 (3H, s), 
1.62-1.75 (3H, m), 1.91 (3H, s), 2.31-2.42 (2H, m), 2.52-2.63 (2H, m), 2.73-2.81 (1H, m), 3.02-3.11 (1H, 
m), 3.72 (3H, s), 4.21-4.43 (4H, m), 5.02-5.11 (3H, m), 8.01 (1H, s). δC (75 MHz, CD3OD): 11.4, 16.5, 20.5, 
31.8, 33.2, 55.0, 62.9, 64.0, 70.8, 83.1, 120.0, 123.7, 124.2, 135.0, 162.5, 166.1, 170.8, 173.0, 201.2.  MS: 
C23H30N2O8S m/z (ES+) 494.2 [M+].  HRMS: Calculated for C23H30N2O8S 494.1723, found 494.1676. 
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